Table 1.
Patient Demographics: Infected and Noninfected
| Infected (n = 33) | Noninfected (n = 182) | P Value | |
|---|---|---|---|
| Age, y, mean (SD) | 60.4 (10.0) | 55.5 (13.6) | .018 |
| Female sex | 14 (42) | 70 (38) | .668 |
| Comorbidity | |||
| Diabetes mellitus, type 1 or 2 | 10 (30) | 72 (40) | .314 |
| Rheumatologic autoimmune condition | 7 (21) | 19 (10) | .081 |
| Person living with HIV | 0 | 3 (2) | .458 |
| Obesity | 3 (9) | 65 (36) | .002 |
| Malignancy, active or in remissiona | 5 (15) | 26 (14) | .896 |
| Chronic obstructive pulmonary disease | 5 (15) | 12 (7) | .094 |
| End-stage renal disease | 3 (9) | 17 (9) | .964 |
| None | 8(24) | 32 (18) | .366 |
| Race | .006 | ||
| Asian | 1 (3) | 5 (3) | .928 |
| Black/African American | 10 (30) | 102 (56) | .006 |
| White/Caucasian | 22 (67) | 61 (34) | <.001 |
| >1 race | 0 | 12 (7) | .129 |
| Other | 0 | 2 (1) | .545 |
| Transplanted organ | <.001 | ||
| Lungb | 23 (70) | 33 (18) | <.001 |
| Heart | 1 (3) | 20 (11) | .157 |
| Kidney | 8 (24) | 121 (66) | <.001 |
| Simultaneous heart/kidney | 1 (3) | 4 (2) | .770 |
| Simultaneous pancreas/kidney | 0 | 3 (2) | .458 |
| Simultaneous heart/liver | 0 | 1 (0.6) | .670 |
| Retransplanted | 4 (12) | 24 (13) | .867 |
| Rejection in last 1 yc | 10 (30) | 30 (17) | .076 |
| Induction therapy | <.001 | ||
| Lymphocyte depleting | 3 (9) | 80 (44) | <.001 |
| Basiliximab | 25 (76) | 64 (35) | <.001 |
| Combination therapyd | 1 (3) | 8 (4) | .719 |
| None | 0 | 6 (3) | .290 |
| Other, including unknown | 4 (12) | 24(13) | .867 |
| Immunosuppressione | |||
| Belatacept-containing regimen | 23 (70) | 129 (71) | .891 |
| CNI-containing regimen | 25 (76) | 94 (52) | .010 |
| Corticosteroid-containing regimen | 32 (97) | 170 (93) | .429 |
| Antimetabolite-containing regimen | 21 (64) | 122 (67) | .704 |
| mTOR-containing regimen | 3 (9) | 13 (7) | .695 |
| 3 concomitant immunosuppressants | 17 (52) | 126 (69) | .047 |
| 4 concomitant immunosuppressants | 11 (33) | 30 (16) | .023 |
| 5 concomitant immunosuppressants | 0 | 3 (2) | .458 |
| Median total belatacept doses, No. (IQR) | 9 (4–27) | 13 (4–40) | .139 |
Data are presented as No. (%) unless noted otherwise.
Abbreviations: CNI, calcineurin inhibitor; mTOR, mammalian target of rapamycin.
aMalignancy included all solid and hematologic malignancies, active and in remission.
bOne patient received a lung transplant and then years later received a kidney transplant and is counted as a lung transplant here.
cLast 1 year preceding infection, death, or study conclusion as applicable.
dCombination induction therapy included 2 patients with basiliximab and antithymocyte globulin, 6 with antithymocyte globulin and another agent (eg, intravenous immunoglobulin or belatacept), and 1 with basiliximab and belatacept.
eImmunosuppression used in the 6 months preceding infection, study conclusion, or death, as applicable. Antimetabolite regimen includes azathioprine, mycophenolate mofetil, or mycophenolic acid. CNI regimen includes tacrolimus and cyclosporine. mTOR inhibitors include sirolimus and everolimus.